- CytoSorbents Secures $20 Million Credit Facility
- CytoSorbents Announces Regulatory Approval of CytoSorb® in Taiwan
- CytoSorbents Announces the Launch and Immediate Availability of the PuriFi™ Blood Pump in the European Union
- CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting
- CytoSorbents STAR Registry Data on Patients on Ticagrelor Undergoing CABG Surgery with CytoSorb Presented at EuroPCR 2024. Named Top Five Finalist for Best Scientific Abstract
- CytoSorbents Reports First Quarter 2024 Results
- CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe
- CytoSorbents to Report First Quarter 2024 Operating and Financial Results
- STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
- CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
More ▼
Key statistics
On Friday, Cytosorbents Corp (CTSO:NAQ) closed at 0.9089, 29.84% above the 52 week low of 0.70 set on Jul 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.86 |
---|---|
High | 0.925 |
Low | 0.831 |
Bid | 0.83 |
Offer | 0.94 |
Previous close | 0.86 |
Average volume | 143.74k |
---|---|
Shares outstanding | 54.31m |
Free float | 52.57m |
P/E (TTM) | -- |
Market cap | 46.70m USD |
EPS (TTM) | -0.5869 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 21:00 BST.
More ▼